Hong Kong Stocks Midday Update: Hang Seng Index Up 0.28%, Biotech Index Extends Gains

Stock News07-16

Hong Kong equities advanced during the morning session, with the benchmark Hang Seng Index climbing 68 points (0.28%) to 24,658. The Hang Seng Tech Index gained 0.61% amid robust turnover of HK$157.9 billion.

Biotechnology stocks maintained their upward trajectory following China's 2025 healthcare policy update. The National Healthcare Security Administration unveiled a new commercial insurance catalog supporting innovative drugs facing reimbursement challenges, propelling the Hang Seng Biotech Index higher. Constituents outperformed: Livzon Pharmaceutical Group (01513) surged 12.69%, Luye Pharma Group (02186) jumped 7.69%, Fosun Pharma (02196) rose over 6%, and Akeso Inc. (09926) advanced 6.88%.

Kuaishou Technology (01024) gained 1.76% to a two-year peak as UBS projected advertising acceleration in Q2 and valuation upside for its Kling business. Online travel agencies showed strength amid stable competition: Tongcheng Travel (00780) added 3.32% while Trip.com Group (09961) increased 2.57%. ANTA Sports Products (02020) rose 2.73% after reporting mid-single-digit H1 retail growth for its flagship brand.

Notable movers included Livzon Pharmaceutical (01513), which soared 12.69% after completing patient enrollment for Phase II trials of cardiovascular drug H001 capsule. Innoscience Technology (02577) climbed 6.41% on plans to substantially expand 8-inch GaN wafer capacity within five years. China XLX Fertiliser (01866) gained 3.83% after regulators convened potassium fertilizer supply meetings, with analysts predicting sustained industry momentum.

Chongqing Machinery & Electric (02722) skyrocketed over 17% as domestic AI data center developments accelerated, benefiting engine supplier Chongqing Cummins. Jiufang Zhitong (09636) leapt 10.18% following a HK$746 million share placement announcement for blockchain financial resource development.

On the downside, Smoore International (06969) slid 3.55% after guiding for 21-35% interim profit decline. Pharmaron (03759) dropped 5.24% post-profit warning, forecasting 36-39% H1 net profit contraction.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment